Oza’s new Miami Beach home was built in 1936 and sculpted by architect Lawrence Murray Dixon, who owned it as a personal ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $26.36 which represents a decrease of $-2.19 or -7.67% from the prior close of $28.55. The stock opened at $26.04 and touched a low ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...

NVO is on track for its biggest daily and weekly percentage losses on record, as well as a fourth-straight loss. Shares now ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this ...

BofA notes that yesterday morning, the FDA issued a new decision determining that the shortage of Eli Lilly’s (LLY) tirzepatide was resolved.

It's that time of the year; We all likely indulged more than we'd like to admit for the holidays and put on a few extra ...